Conference Handbook 2013

Translating UK scientific excellence into global therapeutic strategies ASTRA AD sponsors 3

On Helix 2013 Sponsors contents Platinum Sponsors Introduction 4

Advisory Board 6-7

Keynote Speakers 8

Silver Sponsor Speaker Profiles 9-15

Agenda 16-17

Artist in Residence 19

Floor Plan 20 Coffee Break Sponsors Exhibitors 21-29

Corporate Patron Supporters

Corporate Sponsors

Event Partner

Media Partners Partners

Media Partners 4 introduction

welcome

Dear ON Helix Participant,

Welcome to our brand new Conference: ON Helix. Harriet Fear One of the key issues described everyone would be willing to take CEO, One Nucleus by many researchers is how to part. I was over the moon when they overcome the innovation gaps all said yes – a huge endorsement on the translational research that we had hit on a vital and exciting pathway. This includes identifying theme. Please see pages 6 and 7 for barriers on which to concentrate, the Advisory Board. finding funding and meeting the right networks. You can expect stimulating keynote speeches, exceptional world class case These topics are of course covered study examples of collaborations and by many conferences, but for the technologies and plenty of networking. first time in the UK, One Nucleus is bringing together all these elements The One Nucleus team and I in one event under one roof for know you will make full use of the one day. Excellence in translational presentations, debate, networking and research is a core skill of many One the exhibition hall to catch up with Nucleus members and it seemed old friends and make some new ones, entirely appropriate that we should update yourselves on trends in the showcase that excellence to the UK sector and create and scope out new and wider community; especially if it business opportunities. will stimulate and inspire young and I wish everyone an excellent event. emerging companies to follow in the footsteps of the people you will hear and learn from today.

ON Helix aims to inform delegates of how to turn early stage inventions and ideas into innovative health treatments. We will present the UK landscape of the business environment, funding, scientific and clinical research excellence. It will be a unique knowledge-sharing environment between academia and business.

I would like to take this opportunity to thank our fantastic ON Helix Advisory Board for all their support. Back in 2012 I compiled a ‘dream list’ of Advisers for the event – not expecting that

6 advisory board

Jane Dancer COO, F-star Jane Dancer joined F-star as their Chief Operating Officer in April 2012. Prior to that she was VP Business Development at Cellzome and Director, Business Development at MedImmune Ltd (formerly Cambridge Antibody Technology (CAT)) Jane spent the first part of her career in the agrochemical industry where she held research and project management roles in Aventis Crop Science, AgrEvo UK Ltd and Schering Agrochemicals Ltd,. Jane has an MBA from The Judge Institute of Management Studies, University of Cambridge and a PhD and degree in Natural Sciences from the University of Cambridge

Sue Dunkerton Co-Director, HealthTech and Medicines Knowledge Transfer Network Sue Dunkerton is Co-Director of the HealthTech and Medicines Knowledge Transfer Network (sponsored by the Technology Strategy Board), established to support and accelerate innovation in the life sciences sector for human health. Sue has a background in materials engineering and, following a career spanning aerospace and electronics, moved into the medical sector around 1990. She has worked in the medical devices and technologies area predominantly, with specialism in the KTN spanning assisted/independent living, diagnosis for infectious agents and more recently regenerative and stratified medicine. Sue works closely with UK government and particularly the Technology Strategy Board, to help represent business input to future technology and innovation strategy. Sue sits on a number of bodies to support healthtech businesses in the UK, notably: • Assisted Living Innovation Platform Steering Group • Stratified Medicines Innovation Platform Steering Group • BIS/OLS SME Competitiveness Working Group, • NIHR Medical Devices Clinical Studies Working Group • Institute of Materials Biomedical Applications Division • EPSRC Strategic Advisory Team for Healthcare • Medilink UK.

Jon Green Vice President, Business Operations, MedImmune | One Nucleus Chair Jon has held posts in academia as a member of scientific staff in the Biochemistry Department, Imperial College and then as a Senior Scientific Officer with the Medical Research Council. Jon joined Cambridge Antibody Technology (CAT), in 1992 as a Senior Scientist, initially working on several drug discovery projects before moving across to operational management. Jon now holds the post of VP Business Operations at what is now MedImmune, a wholly-owned subsidiary of AstraZeneca formed through the merger of CAT and MedImmune Inc. Jon is responsible for leading the site operations of the Cambridge R & D facilities, with specific focus on property, engineering, laboratory and office facilities, security, EHS, procurement, and risk management. Jon is also currently Chairman of the Board of One Nucleus, the largest Life Sciences membership organisation in Europe and sits on the Steering committee of the Pharmaceutical Industry Security Forum. Jon has an MPhil in molecular biology, is a Chartered Biologist, a Fellow of the Society of Biology and a Fellow of the Royal Society of Arts and Manufacturing. Jon also is a member of the Security Institute, the British Institute of Facilities Management and the British Association of Research Quality Assurance.

Geoff Lawton Founding Director, INMedD Geoff Lawton has extensive experience in new medicines discovery in large and small companies. His roles included Director of Chemistry within Roche UK, and Vice-president Chemistry and Preclinical Sciences at Roche Palo Alto. He was for five years the research member of the global therapy area strategy planning team for inflammatory diseases, aligning research with the clinical development and marketing parts of the business. Since 2001 Geoff has provided scientific and strategic evaluation and advice on drug discovery as an independent consultant to organisations including biopharmaceutical companies, venture investors, CROs, medical research charities and academic groups. He was Research Director with Lectus Therapeutics a start-up aiming to deliver next generation ion channel modulating medicines. Geoff is a founding director of INMedD, a social enterprise, and is a board member of Antabio which develops new drugs to limit bacterial virulence. He also serves on the Scientific Advisory Board of Peakdale Molecular. advisory board 7

Ruth McKernan Senior Vice President, Pfizer | CSO, Neusentis Ruth McKernan is Senior Vice President of Pfizer and Chief Scientific Officer at Pfizer ‘s Cambridge Research Unit, Neusentis. Born in Scotland, she gained her PhD at London University’s Institute of Psychiatry studying the mechanism of action of antidepressant drugs. After two years on a Fulbright Scholarship at the University of California in San Diego, she joined the pharmaceutical Industry. Ruth spent 17 years at Merck, becoming head of the Merck Neuroscience Research Centre in Harlow in the UK in 2001. She joined Pfizer in 2005 as Vice President of Biology in Sandwich. Since then she has been head of the Research Technology Centre in Boston and in 2008 she started Pfizer Regenerative Medicine, a new area of innovation for the company. In 2010 she was additionally appointed as head of the Sandwich Site. In April 2011, she formed the new Cambridge Research Unit, Neusentis. She sits on the Board of Pfizer, UK, and on multiple Advisory Boards including Cancer Research Technologies, She is also a member of the Medical Research Council. Scientifically, Ruth is best known for her research in neuroscience, and is the author of over 130 publications and 15 patents. She has also won awards for science writing and her first book for non-scientists, Billy’s Halo, was short-listed for the 2007 MIND awards.

Alan Palmer CSO, MS Therapeutics | One Nucleus Board Member Alan Palmer is an internationally recognised neuroscientist and a serial entrepreneur, whose career has focussed on neurodegenerative disorders and their treatment. Currently, he is (i) a Board member of Cerebroscience Ltd, MS Therapeutics Ltd (MST) and One Nucleus Ltd; (ii) a visiting Professor at both University College London and the University of Reading; (iii) Life Science Entrepreneur in Residence at the University of Bristol; (iv) a Fellow of the Society of Biology; and (iv) a member of the Scientific Advisory Board of both GE Healthcare Medical Diagnostics Ltd and Pharmidex Pharmaceutical Services Ltd (Pharmidex). Alan has over 100 peer-reviewed papers to his name, 35 of which are highly cited (> 50 citations); total number of citations > 6,000. Formerly, Alan was: (i) voted London Biotechnology Network Entrepreneur of the Year; (ii) Chairman of the Society for Medicines Research;. (iii) a member of the UK Government’s Biotech Pharma Sector Advisory Group; (iv) Group Leader, Wyeth Research Ltd; (v) Principal Investigator, Alzheimer’s Disease Research Centre, University of Pittsburgh Medical School (UPMC); and (vi). Principal Investigator, Head Injury Research Centre, UPMC. He has founded or co-founded a number of companies, including Cerebroscience, MST, New Medicines Discovery, Pharmidex, Cerexus, and Cerebrus (now Vernalis).

Professor Sir Bruce Ponder La Ka Shing Professor of Oncology, Cambridge University | Director, Cancer Research UK Cambridge Research Institute Professor Sir Bruce Ponder established one of the first clinics for familial cancer and contributed to gene discovery and genetic epidemiology in thyroid, breast and ovarian cancer. His focus is now on common genetic variation and cancer susceptibility. Over the past 10 years he has led the development of a new laboratory and clinical centre for cancer research in Cambridge, culminating in 2007 with the opening of the new CRUK Cambridge Research Institute. He is President of the British Association for Cancer Research, and was knighted in 2008 for ”services to medicine”. His interest in lung cancer is recent, and follows from the challenge of understanding the mechanisms of polygenic susceptibility to cancer and possible applications to prevention.

David Tapolczay CEO, Medical Research Council Technology Group (MRCT) Dr David Tapolczay has 28 years experience of R&D management; his past roles include joint worldwide head of chemistry for Zeneca agrochemicals and senior manager of chemical development for Glaxo. He was responsible for the rapid growth of Cambridge Discovery Chemistry and was a key figure in two successful sales of the company initially to Oxford Molecular and then Millennium Pharmaceuticals. Post this last acquisition David was VP of Pharmaceutical Sciences with responsibility for over 230 scientists. On leaving Millennium David was a founder of Pharmorphix Ltd which was acquired by Sigma Aldrich Fine Chemicals in August 2006. He has also been involved with the start up of 5 companies all of which are still trading and one of which has been AIM listed. He was most recently VP of Technology Development for GSK pharmaceuticals and is currently the Chief Executive Officer of the Medical Research Council Technology Group (MRCT). David has an international reputation in the pharmaceutical industry as well as an outstanding academic track record with a considerable number of patents and publications. He was a visiting Professor at Sussex University and has previously held the position of visiting lecturer at Nottingham, Reading and Durham Universities and a member of both the Technical Opportunities Panel and the User Panel of the EPSRC. In addition he is a non executive director for several biotech companies. 8 keynote speakers

Sir William Castell Chairman of the Wellcome Trust Sir William Castell is Chairman of the Wellcome Trust, a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. Prior to taking up this role in 2006 Sir William was President and Chief Executive Officer of GE Healthcare, the global medical diagnostics and biosciences business of the General Electric Company, of which he was also a Vice Chairman. Before its acquisition by GE in 2004, Sir William was Chief Executive of Amersham plc. Sir William retired as a Director of the General Electric Company in April 2011 and in 2012 retired from the board of BP having served for six years, latterly as senior independent director. Bill Castell is Chairman of the Board of Trustees of Chichester Festival Theatre; Chairman of the High Street Fund; and former Chairman of The Prince’s Trust. He is an Honorary Fellow of Green Templeton College, University of Oxford; an Honorary Fellow of the Academy of Medical Sciences; and a Trustee of the Education and Employers Taskforce.

Sir Mike Rawlins Chair of Eastern AHSN | President of The Royal Society of Medicine After obtaining his undergraduate medical degree at St Thomas’ Hospital in 1965, Sir Michael completed his post-graduate training in clinical pharmacology and general medicine at St Thomas’, Hammersmith and the Karolinska Institute in Stockholm From 1973 to 2006, Sir Michael was the Ruth and Lionel Jacobson Professor of Clinical Pharmacology at Newcastle University, where he undertook research into the safety and efficacy of new and established pharmacological treatments. At the same time he was consultant physician to the Newcastle University Hospitals where he practised clinical pharmacology and general internal medicine. He also held the position of consultant physician and consultant clinical pharmacologist to the Newcastle Hospitals NHS Trust. He became a member of the Committee on Safety of Medicines in 1980 and served as chairman from 1993 to 1998. He was appointed chairman of the Advisory Council on the Misuse of Drugs in 1998 and served until 2008. Sir Michael has been chairman of the National Institute of Health & Clinical Excellence (NICE) since its formation in 1999. He is also an Honorary Professor at the London School of Hygiene and Tropical Medicine, University of London, and Emeritus Professor at the University of Newcastle upon Tyne. He has delivered the Bradshaw (1986), William Withering (1994), Samuel Gee (2006), and Harveian (2008) lectures at the Royal College of Physicians. He was awarded the Hutchinson Medal in 2003, the Galen Medal in 2010, and a Lifetime Achievement Award from the International Society of Pharmacoeconomics and Outcomes Research in 2011. In 2010 he established the All-Party Parliamentary Group for Huntington’s disease in the UK Parliament. He was appointed Knight Bachelor in 1999 for services to the improvement of patient protection from the side effects of medicinal drugs.

Andy McMenemy Inspirational Speaker | Personal Performance Development Coach and Mentor Andy McMenemy is best known through the British media when, in 2011, he set out to complete a World Record bid in an epic challenge to run 66 Ultra Marathons in 66 consecutive days in the 66 official cities of the UK, whilst raising money for ABF (Army Benevolent Fund). Despite crippling injuries, including a damaged Achilles tendon on day 2 and strong medical advice to abandon his attempt, he carried on running – and succeeded against the odds. Prior to his ultra-marathon attempt, Andy successfully completed some of the World’s toughest endurance races including the infamous Marathon des Sables and the Namibian Desert 24hr Ultra Marathon. In 2012, he was chosen to carry the Olympic Torch in the run-up to the London 2012 Games.

Andy is an entertaining, thought provoking and inspiring speaker. He talks of the emotional power of a ‘Dream’ and how to endure the pain of the ‘Struggle’, and then learn what it feels like to taste ‘Victory’ when you challenge the limits which you place upon yourself. speaker profiles 9

Keith Blundy CEO, Cancer Research Technology Keith joined CRT in 1998, became COO in 2004 and was appointed CEO in 2007. Since then he has overseen the launch of a £50m Cancer Research Technology Pioneer Fund in partnership with the European Investment Fund (EIF) to bridge the UK funding gap between cancer drug discovery and early treatment development. He has initiated risk sharing discovery alliances with AstraZeneca and Teva (formerly Cephalon), the establishment of CRT Inc in Boston (USA) as a business development arm of CRT and the further globalisation of CRT’s cancer IP development and commercialisation through becoming a partner of Cancer Therapeutics Pty in Melbourne, Australia. After completing a PhD at the John Innes Institute and a post doctoral Fulbright scholarship in the US on the regulation of plant gene expression, he spent 10 years managing and commercialising agricultural biotechnology programmes before transitioning to healthcare through business development. Keith has a BSc and PhD in genetics and an MBA from the London Business School. He was formerly a director of KuDOS Pharmaceuticals Ltd and Mission Therapeutics and currently is on the board of Cytosystems Ltd and Cancer Therapeutics Pty. He is a member of Cancer Research UK’s Scientific Executive Board. The title of Keith’s presentation will be: Best of Both: Drug Discovery Alliances Between Academia and Industry.

Chas Bountra Head, Structural Genomics Consortium (SGC) | Professor of Translational Medicine and Associate Head, Medical Sciences, University of Oxford Chas Bountra serves on numerous public/ charitable funding committees, journal review panels, scientific advisory boards for academic drug discovery programmes, biotechs, pharmas and VCs. He has in the past five years helped attract nearly £65M of research funding to the University, has led the organisation of several international scientific conferences in Oxford and is facilitating the university’s reputation as a centre for drug discovery. Prior to coming back to Oxford five years ago, Chas was Head of Biology at GSK. During a six year period, his group generated >30 clinical candidates, facilitated >20 clinical POC studies, progressed five assets into Phase III studies and established two new Translation research units in Singapore and Ireland. Chas built the biological rationale leading to the development and launch of Alosetron, and was the first to show that neurokinin NK1 receptor antagonists are anti-emetic (drugs now on market). He has therapeutic expertise in neuro-psychiatry, gastro-intestinal, inflammation and cancer, and “know- how” of all stages of the drug discovery and development process. He has given over 300 invited lectures. In 2012 he was voted one of the “top innovators in the industry”.

Miles Carroll Deputy Director Head of Research, Public Health England Miles Carroll joined the Health Protection Agency as Deputy Director Head of Research at Porton Down, in September 2008. His department has a significant number of translational research programmes in the development of infectious disease vaccines, therapeutics and diagnostics. Many of these programmes are in collaboration with the biotech and Pharma sectors. Miles gained his PhD on development of recombinant vaccines from the Medical Faculty at the University of Manchester which enabled him to obtain an International Fogarty Fellowship at the National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA. On his return to the UK, Miles Joined Oxford Biomedica as Vice President of Immunotherapy where he invented and lead the pre-clinical and clinical development of the cancer vaccine TroVax that was subsequently out-licensed to Sanofi Aventis . In 2004, Miles joined the small molecule R&D company, MNL Pharma as CSO before working with UK universities and government research institutes in 2006 to raise external funding to commercialise their technologies. Professor Carroll’s expertise is in the field of recombinaint vaccines with a special interest in smallpox vaccines. He has served on several US Government agency review panels for the development of medical countermeasures. Miles is currently the PI on a portfolio of USG funded biodefense projects. Miles has published over 50 scientific articles and been awarded 10 granted patents. He is a member of research council translational research funding committee and also holds an Honorary Chair in Vaccinology at the Medical Faculty of the University of Southampton.

Kevin Cox CEO, Imanova Kevin has been involved in the life science industry for over 18 years, primarily in leading high-growth, high-tech businesses. Kevin was appointed CEO of Imanova in 2011. Imanova is a unique joint venture between the MRC, and three leading London HEIs (Kings, UCL, Imperial). The business acquired the assets of GSK’s Clinical imaging Centre and has been set up as an independent company to drive innovation and growth in advanced imaging sciences. Kevin chaired the advisory committee of BioNow and UKTI’s Bio/Pharma Sector Advisory Group, was a member the UK’s Life Science Marketing Strategy Board and is a member of the SMIP advisory board for TSB. Kevin took his degree in Chemistry at Sheffield University and a D.Phil at Oxford, before joining ICI. 10 speaker profiles

Susan Galbraith VP and Head of Oncology, iMed, AstraZeneca Susan Galbraith trained as a Clinical Oncologist in the United Kingdom. She studied Medicine at Manchester and Cambridge Universities. She was admitted to Membership of the Royal College of Physicians in 1992, and then trained in Clinical Oncology in London. She gained Fellowship of the Royal College of Radiologists in 1997. She then completed a PhD at the University of London involving translational work on a vascular-targeting agent. Susan joined the Clinical Discovery Oncology group at Bristol-Myers Squibb in 2001. Susan was closely involved in the in-licensing of ipilimumab from Medarex, elotuzumab from PDL, the acquisitions of Adnexus and Medarex and research collaborations with Exelixis. She held increasing levels of responsibility becoming VP for Oncology and Immunology Early Development, and then latterly taking on responsibility for the Clinical Biomarker team. Susan joined AZ in September 2010, as Head of the Oncology iMed responsible for Oncology Discovery and Early Development to Proof of Concept

John Haurum CEO, F-star John Haurum joined F-star in May 2012. Previously he was VP Research, Biologics Products at ImClone Systems, NY, and the Chief Scientific Officer and a co-founder of Symphogen A/S, Denmark. After graduating in 1992, Dr. Haurum received a D.Phil. in immunology from the Institute of Molecular Medicine, University of Oxford, England. Subsequently, he took up a position at the Danish Cancer Society and completed his medical training. He has extensive research experience in molecular immunology and biochemistry and served as a consultant for several biotech companies. He is a“Pathfinder” and holds a Scandinavian International Management Institute diploma in “Managing Medical Product Innovation”. He is a dynamic biotech leader and executive manager with broad biopharmaceutical business, research, and drug development experience, including experience in integration of innovation, drug discovery, and preclinical product development. He has a proven track record in leading biologics drug product candidates through all phases of discovery and preclinical development, manufacturing and regulatory filing. Through his career he has obtained significant experience with business development and VC financing activities, and he has lead the establishment of several collaborative project Joint Steering Committees in both Japan, US, EU, as well as had overall responsibility for Intellectual Property Rights.

Philipp Holliger Program Leader, MRC Laboratory of Molecular Biology Phil Holliger is a Program Leader at the MRC Laboratory of Molecular Biology in Cambridge. His research spans the fields of chemical biology, synthetic biology and in vitro evolution. His work has been published in major journals (e.g. Science, Cell, PNAS, Nature Biotechnology etc) and has led to numerous patents. His recent work on synthetic genetic polymers has also gained significant media attention and featured in Scientific American’s 10 World Changing Ideas. He has been a consultant to several successful biotech companies including Cambridge Antibody Technology, Solexa / Illumina, Domantis and GSK.

Duncan Holmes European Head, Discovery Partnerships with Academia, GlaxoSmithKline European Head of Discovery Partnerships with Academia (DPAc), a GlaxoSmithKline initiative that creates integrated partnerships with academic groups to undertake early drug discovery and translate innovative research into medicines. Duncan established DPAc in late 2010, successfully developing the first collaborations in the UK, before the initiative was expanded globally. Multiple projects are now up and running with academics at European institutions. Duncan has previously led both chemistry and multidisciplinary departments at GlaxoSmithKline undertaking drug discovery across a range of therapeutic areas, including in recent years respiratory diseases and inflammation, delivering many quality candidates that have progressed to Phase II clinical trials and beyond.

Kevin Johnson Partner, Index Ventures Kevin Johnson is a Partner at Index Ventures working out of the London office. Prior to that he was CEO of PanGenetics, an antibody development company based in the Netherlands, and one of the Index Ventures portfolio. Kevin was one of the team at Cambridge Antibody Technology (CAT), heading up research from 1994 onwards. In 1997 he was appointed to the Board, where he held the posts of Research Director and Chief Technology Officer. Kevin led both the development of CAT’s platform technologies, and also their application to the discovery of a number of human antibodies currently in clinical development. Two of these are now marketed, Humira (Abbott Pharmaceutical) and Benlysta (HGS, GSK). He was also part of the management team that floated CAT on the London Stock Exchange (main market). Kevin graduated in Molecular Biology from Edinburgh University and has a PhD in Pathology from Cambridge University.

Are you looking to export? Speak to the experts

UK Trade & Investment is the Government Department that helps UK-based For more information about doing companies succeed in the global economy and assists overseas companies business with the UK and to to bring their high-quality investment to the UK. Its International Trade speak with some of our specialist Advisers (ITAs) around the UK have years of business experience to draw advisors visit on when advising companies. With a global network of 2,400 staff in over www.ukti.gov.uk 100 markets based in British Embassies and other Diplomatic offices around or email the world, UKTI staff can offer local, in-market knowledge and expertise. [email protected]

speaker profiles 13

Scott M. Kahn Member of the Herbert Irving Comprehensive Cancer Center, Columbia University | Scientific Evaluation Counsel, LifeScience Ventures Dr. Scott M. Kahn has been a Member of the Herbert Irving Comprehensive Cancer Center at Columbia University since 1994, and currently serves as Biomarkers Council Chairman for the International Cancer Advocacy Network, where he oversees a panel of expert scientists from academia and industry who collectively assist cancer patients with molecular profiling and clinical management options, using a closely managed and highly personalized approach. Dr. Kahn also serves as Scientific Evaluation Counsel to Lifescience Ventures, Ltd., UK., where he provides expertise to academic scientists seeking to transfer technologies and establish start-up firms. Dr. Kahn’s career includes seminal contributions to cancer biology and cancer theory, as well as the invention and development of innovative, state of the art and cutting-edge biomarker platforms and functional assays. He has discovered oncogenes, functionally characterized signaling pathways, predicted and identified the microsatellite mutator phenotype in colon cancer, worked on associations between biomarkers and clinical therapy, and provided the first evidence leading to the theory of “Oncogene Addiction,” a widely accepted theory for targeted drug therapy. Upon receiving his Ph.D. degree from SUNY@ Stony Brook in Biochemistry and Molecular Biology, Dr. Kahn has held appointments in both academia and industry.

Helen Kuhlman Lead Technologist, Medicines and Healthcare, Technology Strategy Board A cell physiologist and pharmacologist by training, Helen has a 1st Class Honours degree in Biomedical Sciences, and a PhD from the Department of Medicine at the University of Leicester. She joined the Technology Strategy Board in 2010 from the South West Regional Development Agency, where she spent the previous two and a half years developing programmes to support innovation in technology intensive SME’s and building knowledge exchange capacity in the regions research institutions. Prior to that she worked with young biotech companies including, Domantis Ltd (Cambridge), Cambridge Antibody Technology Ltd (now MedImmune Ltd) and SemBioSys Genetics Inc (Calgary, Canada). Within the Technology Strategy Board Helen is involved in leading the overarching Medicines and Healthcare strategy and is responsible for the Biomedical Catalyst programme.

Allan Marchington Founder and Partner, Apposite Capital Allan Marchington is a Partner and Founder member of Apposite Capital. Apposite is a UK based Venture Capital fund with staff in London and San Francisco. Apposite invests on a global basis in healthcare and related areas. Allan is a Board member of a number of companies including Ambit Biosciences Inc., Ambrx Inc., RuiYi, Convergence Pharmaceuticals, and Calchan Ltd. In addition, Allan is a Board member of the BIA, a member of the Liverpool CEP Innovation Board and sits on the Investment committee of the Royal Society of Chemistry Allan was formerly a medicinal chemist at Pfizer. In 1997 he left Pfizer to start his own company Cambridge Discovery Chemistry. In July 2000 Millennium Pharmaceuticals Inc. bought the company and Allan moved to the USA to join the Millennium Management team with responsibility for all technology Investments and European operations. In 2003, he returned to the UK joining Abingworth Management and in September 2005, Allan, with his Partners, founded Apposite Capital.

Anita Marguerie de Rotrou Production Manager, DefiniGEN Definigen Ltd is a recent spin-out from the Vallier Lab at University of Cambridge and provides human liver cells for preclinical drug development and disease modelling applications using human induced pluripotent stem cell (hiPSC) technology. Anita Marguerie is Definigen’s Production Manager and is transferring the technology while setting up the Company’s facility on the Babraham Campus. Anita has more than seven years’ experience in the life science industry including Stem Cell Sciences, Daniolabs and Summit plc. Prior to that, she did postdoc studies at Cancer Research UK and received her PhD in Developmental Biology from the University of London in 2000.

Annabel McLeod Research and Development Tax Credit Specialist and Customer Relationship Manager, HMRC A Research and Development tax credit specialist in HMRC’s Cambridge R&D and Pharmaceutical unit, Annabel has dealt with R&D tax credit claims from the smallest SME to largest household name companies, and from the outset of the first UK R&D tax credit scheme in 2000. As a Customer Relationship Manager, she also coordinates HMRC’s relationship with some of the largest businesses in the Pharmaceutical and Chemical sector over both direct and indirect taxes. She is currently interested to see how the new “Above the Line” tax credit and the new Patent Box scheme work in practice. 14 speaker profiles

Professor Laurence Pearl Professor of Structural Biology, MRC Genome Damage and Stability Centre | Head, School of Life Sciences, University of Sussex Prof. Laurence H. Pearl FRS FMedSci is Professor of Structural Biology in the MRC Genome Damage and Stability Centre and Head of the School of Life Sciences at the University of Sussex. Before that he was Professor of Protein Crystallography at the Institute of Cancer Research in Chelsea, where he was also Chairman of the Section of Structural Biology. His laboratory is internationally recognised for its ground-breaking studies of the structural biology of DNA repair, signal transduction and molecular ‘chaperones’, and for the translation of this basic research to drive drug discovery for the treatment of cancer and other diseases.

David Phillips Partner, SR One David joined SR One in 2008 to pioneer a new function to incubate and spin-out technologies from GSK and subsequently joined the team focusing on European investments. David brings a range of experience to SR One, including senior management roles in sales and marketing, commercial strategy and business development at Glaxo Wellcome, Cephalon, Medical Venture Management, The Automation Partnership and Galapagos. David has significant deal making experience in the pharmaceutical and biotech sectors and has run a number of successful businesses deriving healthy exits for investors. David has a BSc (Hons) in Pharmacology from the University of London and is a member of the Charted Institute of Marketing.

Nick Pope Founder, BioSpring Ltd Nick Pope is the founder of BioSpring Ltd, which assists SMEs & institutions with technology commercialisation & business start-up services. He has a PhD, MBA and IMC which he applies along with 30 years’ experience in the Biotech and Pharma industries, to enabling clients to achieve their aspirations. Previously in biotech business development and venture capital, Nick recently advised The East Midlands AHSN on industrial engagement, co-founded Funds&Fundability (www.networkedpharma. com), and co-authored the Mobius LifeSciences Report. He also sits on the Mobius investment panel, mentors for Warwick Business School; and occasionally blogs on OI and funding, and leads experiential leadership development expeditions.

Oliver Rausch Programme Director, NOCRI Oliver Rausch is Programme Director at the NIHR Office for Clinical Research Infrastructure (NOCRI). As Programme Director, Oliver is responsible for the NIHR Translational Research Partnerships and other industry-focussed NIHR programmes in translational research. The TRPs were established to support collaboration between companies, the NHS and academia in early and exploratory translational research. They provide an internationally unique approach to drive translational research in defined therapeutic areas such as inflammation. The TRPs are establishing a new model for industry to take on the challenges of early drug, device and diagnostic development. Oliver joined NOCRI in July 2012, bringing over fifteen years’ of drug discovery experience in Neurology, Oncology and Inflammation from organisations such as GlaxoSmithKline, UCB Celltech and Cellzome. Prior to joining NOCRI, Oliver held the position of Vice President Biology at Cellzome. He holds a degree in Biochemistry from the Free University in Berlin and a PhD in Biochemistry and Cell Biology from the Institute of Cancer Research in London.

Professor Sir Michael Stratton Director, Wellcome Trust Sanger Insititute Mike Stratton is Director of the Wellcome Trust Sanger Institute, Hinxton, UK. He studied medicine at Oxford University and Guy’s Hospital, specialised in histopathology and obtained his PhD at the Institute of Cancer Research, London. His research is in cancer genetics. Early studies focused on inherited predisposition, notably discovery of the breast cancer susceptibility gene BRCA2. Subsequently, he initiated genome-wide sequencing for somatic mutations in cancer, discovering BRAF mutations in malignant melanoma and describing basic mutational patterns in cancer genomes. speaker profiles 15

Keith Tan Senior Director of Translational Medicine, MedImmune Keith Tan is currently Senior Director of Translational Medicine at MedImmune, Cambridge, UK. He trained in clinical pharmacology at the University of Cambridge and spent the last 19 years working across research and development in the biopharmaceutical industry. He has led multiple clinical projects from first-in-human studies to new drug applications and was most recently the site head for Translational Medicine at Pfizer’s European R&D headquarters. The major emphasis in Keith’s work is the integrated development and application of translational biomarkers, PK/PD, clinical trial methodologies, imaging and molecular profiling to deliver personalized medicine. He has worked in multiple therapeutic areas, with a focus on Neuroscience in the last10 years.

Nick Thomas Principal Scientist, GE Healthcare Dr Nick Thomas is Principal Scientist at GE Healthcare based in Cardiff. He has a BSc in Biochemistry from the University of Glasgow and a PhD from the University of Wales College of Medicine. In a 30 year career with Amersham and GE Healthcare he has held a number of positions in Operations and Research and Development. He is the inventor or co-inventor of over 60 patents in a wide range of technologies including microfabrication, molecular and cellular sensors and cellular imaging. Dr Thomas recently received the GE Edison Award for contributions to research and development.

John Tite Director, Kymab Access John Tite is a Director of Kymab Access. John has a background in immunology, receiving his post-doctoral training at Yale University School of Medicine, and has worked extensively in the areas of vaccines and therapeutic monoclonal antibodies. John was Vice President at GSK where he was responsible for leading the Discovery Biology group in the Biopharm CEDD and was founding CEO of Bicycle Therapeutics, a spin out from the MRC Laboratory for Molecular Biology in Cambridge. He has been involved in a number of academic translational initiatives and is currently a member of the Scientific Advisory Board of MRC-T and the CR-UK Drug Discovery Advisory Group. He was also a member of the DPFS review panel (2008-2012) and was the Chairman of the Board of Trustees of the Edward Jenner Institute for Vaccine Research.

Mark Treherne CEO, Life Science Investment Organisation Dr Mark Treherne is Chief Executive of the Life Science Investment Organisation, which was established by UK Trade and Investment (UKTI) to support overseas investment into the UK: from the earliest R&D collaborations through to clinical trials, commercial operations and partnerships. Mark now has over 25 years’ experience of commercialising R&D in public and private pharmaceutical and biotechnology companies.

David Williams CEO, Discuva David has 28 years’ experience in large Pharma and Biotech, with active involvement in all stages of research from target discovery and translational research through to Phase II clinical studies. In addition, he has successfully forged commercial deals with many major Pharma including Genentech, Roche, Novartis, Bayer and Astra-Zeneca and authored or co-authored over 50 publications and patents. David co-founded the successful AIM-listed oncology drug discovery company Sareum, raising $11m from private/ public sources against a ultimate market value of $55m in six years and as part of the senior management steered Summit plc back to financial and scientific viability. Other major roles in UK/US senior management and research were performed at Millennium Pharmaceuticals, Medivir, Acambis and Roche. David co-founded and is CEO of the Next Generation Antibiotics company Discuva, based in Cambridge UK and deputy chairman of Bactevo, a pioneering Industrial Biotechnology company. 16 agenda

08:00 – 08:45 Registration 12:30 –13:30 Lunch, exhibitor visits, networking

08:45 – 09:00 Welcome from One Nucleus Harriet Fear Case Studies CEO, One Nucleus The collaborative approach to supporting translational 09:00 – 09:30 Keynote address: Impact of science research (James Watson Room) and translational research on the UK economy 13:30 –13:35 Introduction from the Chair Sir William Castell Scott Khan Chair of the Wellcome Trust Columbia University and LifeScience Ventures

09:30 –10:00 Keynote address: The regulatory 13:35 –13:50 Reducing the risks of translation: environment to support A collaborative approach to imaging translational research Kevin Cox Sir Mike Rawlins Imanova Chair of Eastern AHSN | President of the RSM 13:50 –14:05 Best of both: Drug discovery alliance 10:00 –10:15 How industry, academia and between academia and industry Keith Blundy government can work together to Cancer Research Technology impact science and translational research in the UK 14:05 –14:20 Playing to strengths: Discovery Susan Galbraith partnerships with academia VP and Head of Oncology iMed, AstraZeneca Duncan Holmes Discovery Partnerships, GlaxoSmith Kline 10:15 –10:45 Tea/Coffee break, exhibitor visits 14:20 –14:35 Therapeutic antibodies for academic translational The UK contribution in game changing technologies research John Tite for translational research Kymab Access We will explore how the evolution of these fundamental technologies improved the delivery of translational research over the years and nowadays 14:35 –14:50 Pre-competitive collaborations are catalysing science, proprietary drug discovery and the 10:45 –10:50 Introduction from the Chair creation of new companies Sir William Castell Chas Bountra Chair of the Wellcome Trust The Structural Genomics Consortium

10:50 –11:05 Applications of genomics for human 14:50 –15:00 Conclusion from the Chair health Professor Sir Mike Stratton Wellcome Trust Sanger Institute

11:05 –11:20 Atoms and empty space: How structural biology could drive drug discovery – if only you let it Professor Laurence Pearl University of Sussex

11:20 –11:35 Towards a new class of biotherapeutics based on synthetic genetic polymers Philipp Holliger MRC Laboratory of Molecular Biology

11:35 –11:50 Stem cells in healthcare: Improving pre-clinical drug development and human cell therapy Nick Thomas GE Healthcare

11:50 –12:30 Panel discussion with the Chair and speakers on the future of these technologies and what might be the next significant wave agenda 17

12:30 –13:30 Lunch, exhibitor visits, networking 10:15 –10:45 Tea/Coffee break, exhibitor visits

Enabling translational research in the UK

15:30 –15:40 Introduction from the Chair Meeting the translational research challenges Mark Treherne (Conference Hall) Life Science Investment Organisation (LSIO)

15:40 –15:50 NOCRI translational research Introduction from the Chair 13:30 –13:35 Introduction from the Chair partnerships Scott Khan Allan Marchington Columbia University and LifeScience Ventures Apposite Capital Oliver Rausch NOCRI Reducing the risks of translation: 13:35 –13:50 Translating a platform into an 15:50 –16:00 Biomedical catalyst A collaborative approach to imaging oncology pipeline Helen Kuhlman Kevin Cox John Haurum Technology Strategy Board Imanova F-Star

Best of both: Drug discovery alliance 13:50 –14:05 Driving the science to make new 16:00 –16:10 Academic Health Science Network between academia and industry antibiotics Nick Pope EMAHSN Keith Blundy David Williams Cancer Research Technology Discuva 16:10 –16:20 R&D tax credit Playing to strengths: Discovery 14:05 –14:20 Turning an academic discovery into Annabel McLeod partnerships with academia defined hepatocyte products HMRC Duncan Holmes Anita Marguerie de Rotrou Discovery Partnerships, GlaxoSmith Kline DefiniGEN 16:20 –16:30 Public Health England Miles Carroll Therapeutic antibodies 14:20 –14:35 Development and application of a UV Public Health England for academic translational pain model for target identification research and proof of mechanism 16:30 –16:35 Conclusion from the Chair John Tite Keith Tan Mark Treherne Kymab Access MedImmune Life Science Investment Organisation (LSIO)

14:35 –15:00 Panel discussion on investment in translational research 16:45 –17:15 Closing keynote address: The power projects in the UK of positivity Andy McNenemy Allan Marchington, Apposite Capital Inspirational Speaker | Personal Performance David Phillips, SROne Development Coach and Mentor Kevin Johnson, Index Ventures

17:15 –18:30 Drinks reception Life Science Leadership Series

Investment Strategies in Life Sciences 25 September 2013

Cambridge, UK onenucleus.com/events artist in residence 19 Life Science Leadership Series “So beautiful it had to be true” James Watson

Jane Southgate

The artwork produced by Jane Southgate concentrates on her fascination with all things biological and medical, be that the life cycles of birds compared to humans, the anatomy and workings of the brain, the recycling processes in the natural world or the beauty of genetics.

Born in 1973 and later trained in sculpture at Chelsea School of Art, Jane specialises in three dimensional textile based work and employs Investment modest materials – wool, cotton, wire, ribbon – and techniques traditionally considered to be Strategies in Life women’s skills – knitting, sewing, crochet. There is a particular intimacy woven into her Sciences work and an impregnation of emotion that comes through the concentrated labour and intensive hands on relationship to the work. 25 September 2013 The threads she uses weave, both physically and metaphorically, the rich tapestry of genetic and historic information about the very building blocks of life itself. In this exhibition Jane Southgate celebrates the work of all those pioneering scientists who played their part in the discovery of DNA, and extolls the beguiling nature of the microscopic structure itself. Jane has exhibited widely and undertaken many commissions for both businesses and individuals. She has had residencies with the British Trust for Ornithology, Suffolk Wildlife Trust, Manor House Museum, and Stowhealth. She has also researched different projects at Kew Gardens and with a Neurologist. Her work has appeared in neurology magazine ACNR and is due to be on the cover of Cortex later this year. She leads numerous art workshops with a wide variety of groups ranging from children to adults with learning difficulties, OAP’s to business people. If you are interested in buying, exhibiting, or commissioning Jane’s work you can contact her at the following email address; [email protected] or keep up to date with her on her blog; Cambridge, UK www.janevsouthgate.blogspot.com onenucleus.com/events 20 floorplan

James Watson Room

Catering 25 26 27 28 Catering 24 1 23 Gardens 2 22 3

21 4 20 5 6 Catering Conference 7 Hall 8 19 9 18 17

16 10 15 11 14 Catering 13 12 Catering

Registration, Partnering Reception, Café

WC

MAIN ENTRANCE

Drinks Reception in Hinxton Hall exhibitor list 21

1 Affymetrix 15 Peakdale Molecular Ltd

2 Sigma-Aldrich 16 Promega

3 Grundon Waste Management 17 Oxford Biomedical Research Centre

4 Chesterford Research Park 18 Cambridge Research Biochemicals

5 Panasonic Biomedical 19 STARLAB

6 Cambridge Major Laboratories Inc 20 Fisher Scientific UK

7 UK Trade & Investment 21 Public Health England

8 MedImmune 22 Pathology Diagnostics

9 KISS Communications 23 Scottish Development International

10 S-Tech Insurance Services 24 A4PBio

11 Domainex 25 Meso Scale Discovery

12 Stratagem IPM 26 Jaytee Biosciences Ltd

13 MRC Technology 27 Oxbridge Biotech Roundtable (OBR)

14 World Courier 28 BMG labtech

A4PBio provides integrated CRO oversight, Affymetrix® provides powerful tools to BMG LABTECH, specialist in microplate project management and consultancy enable deep understanding of biology reading instrumentation, has earned the services in order to deliver regulatory in the laboratory and translate scientific reputation of being a world leader with compliant bioanalysis and bio-logistics knowledge into routine clinical practice modular and fully upgradeable microplate solutions to the life science sector. for improved human health. We provide reading systems for genomic, transcriptomic, and cellular A4PBio offer client focused solutions • Fluorescence Intensity and Polarisation profiling solutions for the identification, in global laboratory selection, through • Time Resolved Fluorescence validation and development of complex assay development and validation, study • FRET & TR- FRET and simple biomarker signatures. Our sample analysis and data reporting. • Luminescence extensive network of stratified medical Combining this with bespoke logistics • Absorbance researchers are successfully utilising our solutions for the pro-actively managed • AlphaScreen® & AlphaLISA® GeneChip® microarray, QuantiGene® transport of time and temperature • HTRF® multiplex assays, and eBioscience® critical biological samples and • DNA Quantification immunoassay tools to apply their cell-based therapies. • Cell Based Assays research in clinical practice for a wide • Nephelometry A4PBio’s flexible and scalable resources, range of diseases. With assays that using considerable Pharmaceutical, allow the comprehensive analysis and They offer the highest sensitivity, flexibility Biotechnology and CRO experience, application of cytogenetics, genotyping, and reliability and are designed to be deliver individually built, cost effective, pharmacogenomics, expression profiling, easily integrated into automated systems scientifically robust and regulatory gene regulation and cellular biology for higher throughput assays. All BMG compliant outsourcing solutions. information from clinically relevant LABTECH microplate readers are supported sample types, Affymetrix is your partner by a fully qualified team of engineers, Stand 24 of choice from bench to bedside. scientists, and technicians dedicated to bringing you high-quality products of www.affymetrix.com exceptional value and performance. Stand 1 Stand 28 22 exhibitor list

Cambridge Major Laboratories (CML) and Cambridge Research Biochemicals Home to world-leading bioscience WIL Research are partnered to provide (CRB) celebrates 33 years of providing innovators, Chesterford Research Park is world-class services to the research-based custom-made research tools to the Life a key element of the South Cambridge life pharmaceutical industry. Science community. The company, founded sciences cluster only three miles from the in 1980 is the second oldest peptide Wellcome Trust Sanger Institute and the CML is a leader in provision of API chemistry company in the world and specialises M11. The Park’s prestigious environment services, with state-of-the-art facilities and in everything peptide from design to and range of facilities has attracted leaders almost 250 scientists supporting projects synthesis, modification and labelling. CRB in the field including Illumina, BioFocus from compound nomination through also generates target specific antibodies and Isogenica. A 250 acre scheme, the market launch. both to novel proteins and their peptide park delivers high quality accommodation WIL Research is a global CRO dedicated surrogates. Our chemical expertise is further supported by top class central facilities. to listening to customer needs, providing applied to fluorescent labelling of peptides, The Science Village – flexible R&D space in custom-designed product safety toxicological antibodies and proteins and we can advise combinable suites from 1,515 sq ft – is ready research, bioanalytical, & formulation services on appropriate fluorescent dyes or chelates for occupation now. for pharmaceutical, biotechnology, chemical, for fluorescence based applications. CRB London is accessible by train from two agrochemical, & food companies. With works in partnership to offer: Monoclonal nearby stations. Stansted Airport is just 20 approximately 900 personnel, WIL Research antibody production, Chemistry services, minutes’ drive away. offers technological expertise, flexible study Radiolabelling and PNA synthesis. design, & quality results. www.chesterfordresearchpark.com Stand 18 CML and WIL Research are part of the ACAS Stand 4 (American Capital) group of companies. Stand 6

Domainex is a leader in providing premium Grundon’s specialist Clinical Operations As the UK’s leading supplier of laboratory support for academic translational research team has over 15 years experience in chemicals and equipment, Fisher Scientific and has secured funding with numerous dealing with clinical and pharmaceutical distributes own label and branded groups at the forefront of drug target waste, providing a compliant, reliable and products to 40,000 customers in the British research. Once funding is in place, and in full economic service. Isles and selected overseas markets. Our collaboration with the academic partner, plant and headquarters in Loughborough The company owns a range of industry- Domainex has then deployed its significant employ 450 people. leading treatment facilities, including capabilities in medicinal and computational two Hydroclaves and a high-temperature The breadth and depth of our product chemistry, biochemistry and DMPK testing Clinical Waste Incinerator. All collections range creates a virtual one-stop shop for to progress compounds through the are fully documented using our own fleet scientists, a scenario which is conducive to drug discovery process to deliver clinical of dedicated vehicles, from small box vans long-term supply contracts and resulting candidate drugs. up to 40ft articulated double-deck trailers, price stability. Our commitment to supporting translational using ADR-trained drivers. Our company’s ‘shop window’ is a dynamic, research programmes is well demonstrated We provide advice and assistance to ensure our fully interactive web catalogue that by our superb track record with organisations customers are offered the most cost-efficient provides real-time stock availability and a including St. George’s Hospital Medical service consistent with all relevant legislation considerable range of customer oriented School, University of London and the Institute and Department of Health guidelines. features. This is supported by a series of of Cancer Research. paper catalogues covering the entire Stand 3 Stand 11 breadth of general laboratory activity. In the UK, we list over 170,000 products. Stand 20 HOWDI. HELP YOUR DELEGATES TO Easy to use and

“very straight forward. LAUNCH EFFECTIVE COLLABORATIONS &

Over 1500 partnering BRING TRUE VALUE TO THEIR ATTENDANCE meetings were set in “ just one day - our Did you know that 78% of delegates attend events primarily to delegates loved it network with their peers? One Nucleus To help you, the organiser, help your delegates to meet and share knowledge

We have 202 at your event we have created howdi

“delegates and there – a secure, fast and simple to use were 157 partnering“ online partnering solution that meetings set - very enables your delegates to easy to use schedule meetings, BITC upload social media links and plan their day at your event.

BENEFITS For you, the organiser, Delegates maximise event howdi links with any other attendance with meaningful pre- registration system and it’s arranged meetings really cost effective. Delegate data is held on a secure server

Creation of personalised diaries So go to www.ya-yaonline.co.uk/howdi or call +44 (0)207 989 2424 for delegates Howdi is part of the ya-yaonline portfolio of integrated, customised, online View meetings in real time before and onsite at your event event management tools. The tools have been created by event managers, with hands on experience, who understand your needs. Mobile ’app’ increases delegate Our products include networking onsite

Delegates can build relationships, post event, through social media links

Take a look at www.ya-yaonline.co.uk 24 exhibitor list

Jaytee Biosciences Ltd are a nationwide KISS is a creative communications MedImmune is the worldwide biologics company that provides servicing, agency built on the principle of keepings arm of AstraZeneca, with its headquarters calibration, support toHPLC, GC and MS things simple. Simple is better. In an ever in Gaithersburg, Maryland (US) and 10 users in the UK . We are certified to BS increasingly complicated world it’s needed further sites around the world, including EN ISO9001:2008 standard. In addition more than ever. As a multi disciplinary Cambridge, UK. MedImmune has a robust we supply parts and consumables as agency with deep experience in the product development pipeline of over well as fully reconditioned instruments life science sector our services include 120 biologic medicines in R&D, with to all corners of the globe from our HQ strategy and messaging workshops, marketed products including Synagis® in Kent, UK. branding, design, advertising, digital, and Fluenz®. exhibitions, bespoke communications Stand 26 MedImmune Cambridge is the European training and, in conjunction with our biologics R&D hub for neuroscience, partner Zyme Communications, specialist oncology, respiratory, inflammation, life science PR and marketing. autoimmunity, cardiovascular and www.kisscom.co.uk metabolic disease. Based in state-of- www.zymecommunications.co.uk the-art facilities on the outskirts of Cambridge, the MedImmune Cambridge Stand 9 team of over 550 work in integrated project teams with both MedImmune and AstraZeneca colleagues around the world. Stand 8

MESO SCALE DISCOVERY® (MSD) MRC Technology is a technology OBR is a student led initiative with a markets assays and services to the transfer organisation bridging the gap mission to engage our academic and biomedical research community. MSD® between innovative basic science and industry communities on-campus provides fit-for-purpose biomarker new medicines. It adds commercial value and foster a conversation about the assays including singleplex and to cutting edge scientific discoveries healthcare and life-sciences industry. multiplex assays for toxicology, through strategic patent protection, We do this through our events neurodegeneration, cytokines, and creative licensing of intellectual property (routinely attracting high profile metabolic disease research. The assays (IP), partnered research and further speakers and a large audience), our are suitable for studies with pre-clinical, scientific development. interactive blog (the roundtable review) clinical and in vitro samples. MSD’s and business consulting projects for As well as offering technology transfer platform delivers exceptional sensitivity, companies ranging from early stage services to the UK’s Medical Research wide dynamic range and a convenient biotechs to many of the top 5 global Council, the company assists other workflow that enables processing of a pharma companies. Founded in Oxford charitable and academic organisations large number of samples in a limited in 2011, OBR then moved to Cambridge (such as AICR) with IP management and time. MSD also offers assay development and now has chapters in London, commercial development of healthcare- services for customers requiring a San Diego, Manchester, Glasgow, Los related science. MRC Technology works turnkey solution for biomarker studies. Angles and San Francisco with more to develop drug-like candidate molecules on the way. Find out today how OBR Stand 25 to new drug targets, and to translate can partner with your business and the innovative antibody-based drug targets value we can offer. into potent and selective therapeutic antibody candidates. Stand 27 Stand 13 Research & Development

Bringing new healthcare products and interventions to life

www.gov.uk/phe

exhibitor list 27

pathology diagnostics ltd trust in our vision

Oxford Biomedical Research Centre: Panasonic Biomedical Sales Europe BV: Pathology Diagnostics Ltd is an The research expertise of the University Provides sales and support of temperature award-winning GCLP-accredited of Oxford and the clinical skills of Oxford controlled biomedical laboratory histopathology CRO based in Cambridge, University Hospitals NHS Trust have been products, formerly branded SANYO, such specializing in high-quality tissue brought together within the Oxford as low, ultra-low and cryogenic freezers, laboratory and diagnostic analysis for Biomedical Research Centre (BRC). biomedical freezers, high specification preclinical and clinical trial studies & The BRC is a partnership which supports refrigerators, cell culture incubators, companion diagnostics development. Our translational research and innovation plant growth chambers, cycling and facility includes standard histopathology from the bench to the bedside, and it illuminated incubators, laboratory capabilities and state of the art digital is funded by the National Institute for ovens and autoclaves. pathology whole slide scanners, hosting Health Research. It aims to directly benefit and image analysis hardware/software. We Panasonic…the new name for SANYO. patients and improve health care delivery. also collaborate with research scientists Panasonic Biomedical Sales Europe BV. on grant funded technology R&D With renowned international scientists and programmes. We have extensive expertise clinicians working on basic science through UK Office: in the evaluation of academic/preclinical to patient trials and clinical practice, Oxford is 9 The Office Village, North Road, rodent models & human tissues from consistently at the forefront of innovative and Loughborough. Leicestershire. LE11 1QJ. clinical trials and have evaluated > 130 life-saving science. We understand the value Tel (office): +44 (0) 1509 265265 biomarkers in > 75,000 tissue samples to of collaboration and welcome the opportunity Fax.: +44 (0) 1509 269770 date. For further information please visit to build partnerships with industry, academia, e-mail: [email protected] and not-for-profit organisations. www.pathologydiagnostics.com www.panasonic-biomedical.co.uk http://oxfordbrc.nihr.ac.uk/ Stand 22 Stand 5 Stand 17

Peakdale Molecular is a leading UK-based Promega are world leaders in providing Public Health England (PHE) is a new CRO delivering an array of high quality innovative solutions and technical support Executive Agency of the UK Department services for early phase discovery with passion to life science research. Promega’s range of Health that is responsible for and skill. Our customers are drawn from of over 2,000 products enables scientists protecting and improving the nation’s pharma and biotech companies worldwide. worldwide to advance their knowledge in health and wellbeing and reducing genomics, proteomics and cellular analysis inequalities. With ~6000 staff and £1 Using its heritage in the supply of rational promoting increased understanding of billion operational budget, we provide building blocks for medicinal chemistry, the molecular basis of life and potential a nationwide, integrated public health biased screening libraries and custom mechanisms of disease, as well as service supporting people to make synthesis as a springboard, Peakdale identifying targets for drug development. healthier choices and providing expertise, now operates a comprehensive suite information and intelligence. Our of services for hit-to-lead and lead Our extensive range of kits and translational research, development and optimisation studies encompassing reagents, as well as integrated systems testing programmes focus on diagnostics, computational and medicinal chemistry dedicated to life science research and vaccines and other interventions across design, in vitro ADMET studies and PR&D drug discovery, includes specialised healthcare and public health. studies for scale-up. Above all, the most chemicals, enzymes, peptides, antibodies, vital resource we offer is the skill of nucleic acids, novel assays and personal www.gov.uk/phe Peakdale workforce. With over 85% PhD- automation to increase efficiency and Stand 21 level scientists, they relish the challenge improve confidence. of problem-solving within client projects, www.promega.com offering scientific initiative, high levels of communication and utter confidentiality. Stand 16 The Peakdale combination of high productivity, critical thinking and innovation translates into exceptional value-for-money. www.peakdale.co.uk Stand 15 28 exhibitor list

Scottish Development International is Sigma-Aldrich is a leading Life Science STARLAB specialises in the field of the economic development agency for and High Technology company. Our Liquid Handling Technology. STARLAB’s Scotland and is a joint venture between the biochemical and organic chemical success is founded on its expertise in Scottish Government, Scottish Enterprise products and kits are used in scientific automated injection moulding processes and Highlands & Islands Enterprise. and genomic research, biotechnology, for the manufacture of high quality pharmaceutical development, the laboratory consumables for research Since it was founded 11 years ago, SDI has diagnosis of disease and as key and development. Used in laboratories transformed Scotland’s economic outlook, components in pharmaceutical and other throughout the world, STARLAB products attracting some of the world’s biggest high technology manufacturing. We have have a proven track record of performance companies to locate in the country, customers in life science companies, and reliability. As well as pipette tips, growing Scottish exports and creating university and government institutions, pipettes, consumables, gloves and sample over 19,000 new jobs. hospitals and in industry. Sigma-Aldrich storage solutions, STARLAB also has the Scotland hosts one of the largest life operates in 35 countries and has over fastest UKAS accredited pipette calibration science clusters in Europe with significant 9,000 employees providing excellent service in the UK. international presence in research, service worldwide. STARLAB prides itself on being a young development and manufacturing. With a Stand 2 and innovative company that is setting long and remarkable history of medical the standard for reliable deliveries and and scientific discovery stretching back unrivalled levels of customer service. 200 years, Scotland has always been at the forefront of medical innovation. Stand 19 Stand 23

S-Tech has supported life science and Stratagem Intellectual Property UK Trade & Investment (UKTI) works related industries since 1982 by arranging Management Ltd is a full-service, with UK-based businesses to ensure their insurance cover against a wide range Cambridge UK-based, out sourced success in international markets, and of asset, liability and financial risks. We intellectual organisation and encourage the best overseas companies work with you to fully understand your management company with global reach. to look to the UK as their global partner business risks to achieve the widest of choice. Stratagem IPM Ltd fills a developing possible insurance protection. We are need within industry for the provision UKTI has professional advisers both fully independent insurance brokers of strategic advice and intellectual within the UK and across more than 100 with access to insurance markets in the property management for life science, international markets. UK, Lloyds and overseas. Our clients medtech, cleantech and high technology range from start-up to international UKTI has a customer commitment to companies. Stratagem’s qualified organisations both in the UK and abroad. helping its UK and international customers patent and trade mark attorneys use a We offer One Nucleus members discounts by providing a range of services, to a high commercial perspective and hands on off standard policy premiums standard and improve customer service by management approach to enhance the and additional member benefits; please listening to customer feedback. value of IP assets. see check the support supplier page on; We also have a co-ordination role across www.onenucleus.com Stand 12 government to establish a more systematic Stand 10 approach to relationships with companies which are the most economically significant investors and exporters. Stand 7 exhibitor list 29

Incorporated in 1969 and now headquartered in London, UK, World Courier is the largest and most experienced specialty courier service with a network of over 150 company offices operating in more than 50 countries worldwide. World Courier has set the benchmark for worldwide time-sensitive transportation and is the acknowledged leader in delivering customized solutions, cold chain and value- added services in the biopharmaceutical and Lifescience industries. Through its company-owned offices and agents World Courier provides a complete door-to-door, customs-cleared service to more than 220 countries and territories. World Courier is an AmerisourceBergen Company. Stand 14

2013 Events 4 September BioWednesday - London 25 September Life Science Leadership Series Conference: Investment Strategies for Life Sciences - Cambridge

26 September One Nucleus supported event: Biotechnology Investment Forum

– Babraham Research Campus

2 October BioWednesday - London 16 October Network Meeting - Cambridge 14 November Life Science Leadership Seminar - London 27 November Network Meeting - Cambridge 12 December Genesis - London

BioFocus Supports Academic Groups

Fast Facts A HISTORY OF INNOVATION As the global biologics research and development arm of AstraZeneca, BioFocus enables the funding of your concept. MedImmune and AstraZeneca MedImmune is pioneering innovative research and exploring novel pathways Benefit from our: MedImmune is the global biologics research and across key therapeutic areas with the goal of improving patient health. Since • Full spectrum of drug discovery capabilities development arm of AstraZeneca with candidate biologics its founding in 1988, MedImmune has remained committed to scientific • Experienced translational grant writers and vaccines that currently comprise nearly 50 percent of innovation and medical progress, continually looking beyond standard BioFocus enables the funding of your concept. expectations and pushing the boundaries of what is possible. This approach • Network of funding bodies AstraZeneca’s overall R&D pipeline. Benefit from our: full spectrum of drug discovery capabilities | experienced translational grant writers | network of funding bodies to scientific exploration has led to many “firsts” in the industry. During the Pipeline past 25 years, MedImmune has: • Developed and commercialized the first monoclonal antibody (MAb) MedImmune has more than 120 biologics currently in approved by the U.S. Food and Drug Administration (FDA) for research and development with 35 projects in clinical stage prevention of an infectious disease. To date, more than 1 million doses development. To learn more, visit www.MedImmune.com. have been distributed globally.

• Developed and commercialized the first influenza vaccine innovation Independent Guidance to Grant writingProject defence Funding body Employees and Sites in more than 60 years – intranasal delivery. More than 50 million concept review enhance application to funding body budget negotiations Approximately 2,500 full-time employees in the US and UK. doses have been manufactured in the United States alone since 2003.

• Developed the first ever four-strain influenza vaccine. The FDA approved the intranasal quadrivalent vaccine in February 2012. Key Therapeutic Areas Based on years of experience Grant writing and idea generation • Respiratory, Inflammation, Autoimmunity • Discovered the technology that led to Humira® (adalimumab), an • Cardiovascular & Metabolic Disease As part of the interaction model, BioFocus will contribute important anti-TNF antibody now marketed by Abbott • Oncology 1 collaborating with academic and to grant writing and provide ideas on funding mechanisms, Laboratories. • Opportunity-driven in Infection & Vaccines and non-profit institutions, BioFocus but will not seek to retain any IP related to the project; this Neuroscience • Developed and licensed technology for Benlysta® (belimumab) – first will remain with the idea-originating institution. new treatment for active systemic lupus erythematosus in decades, has launched its Academic now marketed by Human Genome Sciences and GlaxoSmithKline.2 A track record of translational Engagement initiative (AEi). • Developed virus-like particle (VLP) technology that led to the creation assistance of Gardasil® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 3 The primary aim of the initiative is to support BioFocus has been assisting researchers to translate their and 18) Vaccine, Recombinant] marketed by Merck. and guide academic groups to identify the best projects to the point of funding for many years. Examples AN INNOVATIVE LEADER, A COLLABORATIVE SPIRIT of such activities include hit finding using high-throughput, In 2007, AstraZeneca acquired MedImmune, and integrated the capabilities of Cambridge Antibody Technology (CAT) as a long- new therapeutic strategy ideas, and to provide an fragment or in silico screening; strengthening hit matter term strategic investment to enhance its capabilities in biologics and diversify its pipeline. Today, MedImmune has one of the most effective and user-friendly mechanism to progress through computational selection and rapid access to robust and promising pipelines in the biologics industry, with more than 120 biologics in research and development and 35 projects these ideas towards high quality chemical matter. analogues; and early ADME profiling to identify potential in clinical stage development. MedImmune has successfully discovered, developed, and applied a number of innovative liabilities and help select the best molecules to progress. technologies, including antibody engineering, cell culture production, and live viral vaccines. Recently, MedImmune developed a BioFocus will continue to enable early-stage projects but is fully human monoclonal antibody molecule that carries its proprietary adaptation (‘YTE’ technology), which extends the molecule’s also highly motivated and well positioned to take the best half-life, the time the molecule is active. projects to preclinical proof of concept and beyond towards candidate nomination. To advance the development of biologics, MedImmune has initiated a number of collaborative partnerships, including: • Joint development and commercialization agreement with Amgen on five monoclonal antibodies from Amgen’s clinical inflammation portfolio, giving MedImmune the most robust inflammation pipeline in the industry. This includes brodalumab, an anti-IL-17 receptor monoclonal antibody that is currently being investigated in a phase III program for the treatment of moderate to severe psoriasis.

• In-licensing agreement with Pfizer Inc. for tremelimumab (CP-675, 206), a CTLA-4 monoclonal antibody, with MedImmune assuming global development rights to tremelimumab to explore its use in a number of potential cancer indications.

• Joint venture with WuXi AppTec, a leading R&D outsourcing company, to develop and commercialize MEDI-5117, a novel biologic for autoimmune and inflammatory diseases, in China. MedImmune is providing technical and development expertise, while WuXi will provide local regulatory, manufacturing, pre-clinical and clinical trial support.

• Collaboration agreement with The Cancer Research Institute (CRI) and the Ludwig Institute for Cancer Research to advance the research of immunotherapy in cancer. Specifically, the research will focus on clinical trials to test novel combinations of For further information on BioFocus’ immunotherapies, including three investigational monoclonal antibodies from MedImmune’s pipeline.

AEi please contact: FOR MORE INFORMATION ABOUT MEDIMMUNE, VISIT WWW.MEDIMMUNE.COM

Professor Julie Frearson: [email protected] 1 Dr. Francesca Sadler: [email protected] Humira is a registered trademark of Abbott Laboratories. 2 Benlysta is a registered trademark of Human Genome Sciences, Inc. Dr. Dave Sheppard: [email protected] 3 Gardasil is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. 11784

Fast Facts A HISTORY OF INNOVATION As the global biologics research and development arm of AstraZeneca, MedImmune and AstraZeneca MedImmune is pioneering innovative research and exploring novel pathways MedImmune is the global biologics research and across key therapeutic areas with the goal of improving patient health. Since development arm of AstraZeneca with candidate biologics its founding in 1988, MedImmune has remained committed to scientific and vaccines that currently comprise nearly 50 percent of innovation and medical progress, continually looking beyond standard AstraZeneca’s overall R&D pipeline. expectations and pushing the boundaries of what is possible. This approach to scientific exploration has led to many “firsts” in the industry. During the Pipeline past 25 years, MedImmune has: • Developed and commercialized the first monoclonal antibody (MAb) MedImmune has more than 120 biologics currently in approved by the U.S. Food and Drug Administration (FDA) for research and development with 35 projects in clinical stage prevention of an infectious disease. To date, more than 1 million doses development. To learn more, visit www.MedImmune.com. have been distributed globally.

• Developed and commercialized the first influenza vaccine innovation Employees and Sites in more than 60 years – intranasal delivery. More than 50 million Approximately 2,500 full-time employees in the US and UK. doses have been manufactured in the United States alone since 2003.

• Developed the first ever four-strain influenza vaccine. The FDA approved the intranasal quadrivalent vaccine in February 2012. Key Therapeutic Areas • Respiratory, Inflammation, Autoimmunity • Discovered the technology that led to Humira® (adalimumab), an • Cardiovascular & Metabolic Disease important anti-TNF antibody now marketed by Abbott • Oncology Laboratories.1 • Opportunity-driven in Infection & Vaccines and Neuroscience • Developed and licensed technology for Benlysta® (belimumab) – first new treatment for active systemic lupus erythematosus in decades, now marketed by Human Genome Sciences and GlaxoSmithKline.2

• Developed virus-like particle (VLP) technology that led to the creation of Gardasil® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] marketed by Merck.3 AN INNOVATIVE LEADER, A COLLABORATIVE SPIRIT In 2007, AstraZeneca acquired MedImmune, and integrated the capabilities of Cambridge Antibody Technology (CAT) as a long- term strategic investment to enhance its capabilities in biologics and diversify its pipeline. Today, MedImmune has one of the most robust and promising pipelines in the biologics industry, with more than 120 biologics in research and development and 35 projects in clinical stage development. MedImmune has successfully discovered, developed, and applied a number of innovative technologies, including antibody engineering, cell culture production, and live viral vaccines. Recently, MedImmune developed a fully human monoclonal antibody molecule that carries its proprietary adaptation (‘YTE’ technology), which extends the molecule’s half-life, the time the molecule is active.

To advance the development of biologics, MedImmune has initiated a number of collaborative partnerships, including: • Joint development and commercialization agreement with Amgen on five monoclonal antibodies from Amgen’s clinical inflammation portfolio, giving MedImmune the most robust inflammation pipeline in the industry. This includes brodalumab, an anti-IL-17 receptor monoclonal antibody that is currently being investigated in a phase III program for the treatment of moderate to severe psoriasis.

• In-licensing agreement with Pfizer Inc. for tremelimumab (CP-675, 206), a CTLA-4 monoclonal antibody, with MedImmune assuming global development rights to tremelimumab to explore its use in a number of potential cancer indications.

• Joint venture with WuXi AppTec, a leading R&D outsourcing company, to develop and commercialize MEDI-5117, a novel biologic for autoimmune and inflammatory diseases, in China. MedImmune is providing technical and development expertise, while WuXi will provide local regulatory, manufacturing, pre-clinical and clinical trial support.

• Collaboration agreement with The Cancer Research Institute (CRI) and the Ludwig Institute for Cancer Research to advance the research of immunotherapy in cancer. Specifically, the research will focus on clinical trials to test novel combinations of immunotherapies, including three investigational monoclonal antibodies from MedImmune’s pipeline.

FOR MORE INFORMATION ABOUT MEDIMMUNE, VISIT WWW.MEDIMMUNE.COM

1 Humira is a registered trademark of Abbott Laboratories. 2 Benlysta is a registered trademark of Human Genome Sciences, Inc. 3 Gardasil is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. 11784 One Nucleus Limited Cambridge (Head Office): The Portway Granta Park Cambridge CB21 6GS United Kingdom +44 (0) 1223 896 450

[email protected] onenucleus.com

Designed by KISS Communications